Please join the NHC and NHC member the EveryLife Foundation for Rare Diseases on Wed., June 21 from 3 – 4 p.m. ET for an in-depth discussion of the FDA’s fourth guidance on patient-focused drug development (PFDD). The meeting will be an opportunity for members of both organizations to explore important topics covered in the guidance and help inform our and our members’ comments. We encourage patient engagement and regulatory subject matter experts to attend this important discussion. Please use this Zoom link to register. This meeting will immediately follow a truncated NHC Medical Innovation Action Team Meeting that will take place from 2:30 – 3:00 p.m ET.